OncoMatch/Clinical Trials/NCT05030298
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Is NCT05030298 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Temozolomide for malignant glioma.
Treatment: Temozolomide — This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pre-operative radiosurgery may improve the odds of brain tumor control and reduce treatment-related side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE III, WHO GRADE IV (WHO)
Excluded: Stage WHO GRADE I, WHO GRADE II
World Health Organization [WHO] grade III-IV, including glioblastoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cranial radiotherapy
Prior history of cranial radiotherapy
Cannot have received: systemic anti-cancer therapy
Exception: within the previous 3 months
Use of systemic anti-cancer therapy within the previous 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Phoenix, Arizona
- Mayo Clinic in Florida · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify